Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone
GSK files for licensure of MMR vaccine in the US
GSK seeks US approval of PRIORIX vaccine licensed in more than 100 countries.
GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps
Fourth indication for mepolizumab in the US for eosinophil-driven diseases.
GSK delivers strong Q2 sales of £8.1 billion, +6% AER, +15% CER Total EPS 27.9p -39% AER, -28% CER; Adjusted EPS 28.1p +46% AER +71% CER
Sales growth driven by strong commercial execution and favourable prior year comparison
Shingrix approved in the US for prevention of shingles in immunocompromised adults
Shingrix approved in the US for prevention of shingles in immunocompromised adults
GSK begins shipping another record supply of influenza vaccine for 2021-22 season in US
GSK increases its volume of influenza vaccines in 2021 to support immunization during pandemic.
ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs
ViiV Healthcare today presented 48-week data from the SALSA study at the International AIDS Society Conference 2021
ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19
ViiV Healthcare today presented positive findings from the CUSTOMIZE trial
ViiV Healthcare to present new data from diverse portfolio and pipeline of 2-drug and long-acting regimens for HIV treatment and prevention at IAS 2021
Data to be presented underscore the commitment to developing innovative treatment and prevention options
GSK announces positive headline results from five Phase 3 studies of daprodustat for patients with anaemia due to chronic kidney disease
Full results to be presented at a medical meeting later this year
GSK and Alector announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases
GSK and Alector to co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases
Elliott Advisors (UK) letter to GSK
The Board of GSK notes the letter issued by Elliott Advisors (UK) Limited (“Elliott”) on 1 July
New GSK to deliver step-change in growth and performance over next ten years driven by high-quality Vaccines and Specialty Medicines portfolio and late-stage pipeline
New GSK to positively impact health of >2.5 billion people next 10 years
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV
Halozyme's technology provides more "shots on goal" to create ultra long-acting HIV medicines with dosing intervals of 3 months or longer
GSK and Vir Biotechnology announce continuing progress of the COMET clinical development programme for sotrovimab
U.S. National Institutes of Health (NIH) COVID-19 Treatment Guidelines updated to recommend use of sotrovimab.
GSK and iTeos Therapeutics announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations
GSK now has the leading portfolio of antibodies targeting the CD226 axis - a key target for next-generation immuno-oncology therapies
Significant and Sustained Drop in Teen and Adult Immunization Rates During Pandemic, Study Shows
Significant and Sustained Drop in Teen and Adult Immunization Rates During Pandemic, Study Shows
GSK to showcase scientific advances and progress in oncology at ASCO and EHA
GSK will showcase innovative approaches to oncology R&D and cutting-edge science at the upcoming ASCO and EHA meetings.
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
Pending positive Phase 3 outcomes and regulatory reviews, the vaccine could be approved in Q4 2021
GSK and Vir Biotechnology announce sotrovimab (VIR-7831) receives Emergency Use Authorization from the US FDA for treatment of mild-to-moderate COVID-19 in high-risk adults and pediatric patients
GSK and Vir Biotechnology announce sotrovimab (VIR-7831) receives Emergency Use Authorization from the US FDA